NCT05518045

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

An Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108 for Injection as Monotherapy or in Combination With Antitumor Therapies in Patients With Advanced Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 392 (estimated)
• Sponsor: LaNova Medicines Limited · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	LM-108	Administered intravenously
DRUG	Toripalimab	Administered intravenously

Timeline

• Start date: 2022-08-26
• Primary completion: 2026-03-31
• Completion: 2026-03-31
• First posted: 2022-08-26
• Last updated: 2026-02-04

Locations

1 site across 1 country: China